Open AccessSafety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials
Author(s) -
David Wirta,
Michael S Korenfeld,
Shane Foster,
Robert Smyth-Medina,
Jason Bacharach,
Shane Kannarr,
Mark Jaros,
Charles B. Slonim
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s322326
Subject(s) - medicine , oxymetazoline , placebo , adverse effect , tolerability , randomized controlled trial , anesthesia , ophthalmology , surgery , adrenergic receptor , alternative medicine , receptor , pathology
An oxymetazoline 0.1% ophthalmic solution was recently approved for treatment of acquired blepharoptosis in adults. This study's objective was to evaluate the safety profile of oxymetazoline 0.1% when administered once daily for 14-84 days.